Caffeine therapy for apnoea of prematurity: Pharmacological treatment

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 5, 2011, Pages 564-571

  Orozco Gregorio, H ^a,d   Mota Rojas, D ^b   Villanueva, D ^c   Bonilla Jaime, H ^a   Suarez Bonilla, X ^d   Torres Gonzalez L ^d   Bolanos D ^b   Hernandez Gonzalez R ^e   Martinez Rodriguez R ^f   Trujillo Ortega, M E ^f  

^a DEPARTAMENTO DE QUÍMICA   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d UNIVERSIDAD DEL VALLE DE MÉXICO   (Mexico)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Apnoea; Caffeine; Methylxanthines; Prematurity

Indexed keywords

AMINOPHYLLINE; CAFFEINE; CAFFEINE CITRATE; METHYLXANTHINE; PLACEBO; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTIFICIAL VENTILATION; ASTHMA; BRAIN BLOOD FLOW; BRAIN INJURY; CEREBRAL PALSY; COGNITIVE DEFECT; CONTROLLED STUDY; DIURESIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SALIVA LEVEL; HOSPITALIZATION; HUMAN; HYPERCALCIURIA; HYPERGLYCEMIA; INFANT; LOADING DRUG DOSE; LUNG DYSPLASIA; MOUSE; NEUROPROTECTION; NEWBORN; NEWBORN APNEA; NEWBORN APNEA ATTACK; NEWBORN INTENSIVE CARE; NONHUMAN; PERIVENTRICULAR WHITE MATTER INJURY; PREMATURITY; REVIEW; SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; VOMITING; WHITE MATTER;

EID: 79959335588     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. al-Alaiyan S, al-Rawithi S, Raines D, Yusuf A, Legayada E, Shoukri MM, el-Yazigi A (2001). Caffeine metabolism in premature infants. J. Clin. Pharmacol., 41: 620-627.
2. Aranda JV, Cook CE, Gorman W, Collinge JM, Loughnan PM, Outerbridge EW, Aldridge A, Neims AH (1979). Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J. Pediatr., 94: 663-668.
3. Aranda JV, Sitar DS, Parsons WD, Loughnan PM, Neims AH (1976). Pharmacokinetic aspects of theophylline in premature newborns. N. Engl. J. Med., 295: 413-416.
4. Aranda JV, Turmen T (1979). Methylxanthines in apnea of prematurity. Clin. Perinatol., 6: 87-108.
5. Atkinson E, Fenton AC (2009). Management of apnoea and bradycardia in neonates. Ped and Child Health, 19: 550-554.
6. Back SA, Craig A, BS, Ling NL, Ren J, Shankar RA, Ribeiro I, Rivkees S (2006). Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann. Neurol., 60: 696-705.
7. Bancalari E (2006). Caffeine for apnea of prematurity. N. Engl. J. Med., 35: 2179-2181.
8. Bathia J (2000). Current options in the management of apnea of prematurity. Clin. Pediar., 39: 327-336.
9. Bauer J, Maier K, Linderkamp P, Hentschel R (2001). Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics, 107: 660-663.
10. Benowitz NL (1990). Clinical pharmacology of caffeine. Annu. Rev. Med., 41: 277-288.
11. Biaggioni I, Paul S, Puckett A, Arzubiaga C (1991). Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Exp. Ther., 258: 5888-5893.
12. Carter AJ, O' Connor WT, Carter MJ, Ungerstedt U (1995). Caffeine enhances acetylcholine release in the hippocampus in vivo by a selective interaction with adenosine A1 receptors. J. Pharmacol. Exp. Ther., 273: 637-642
13. Cazeneuve C, Pons G, Rey E, Treluyer JM, Cresteil T, Thiroux G, D'Athis P, Olive G (1994). Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br. J. Clin. Pharmacol., 37: 405-412.
14. Chardon K, Bach V, Telliez F, Cardot V, Tourneux P, Leke A, Libert J (2004). Effect of caffeine on peripheral chemopreceptor activity in premature neonates: interaction with sleep stages. J. Appl. Physiol., 96: 2161-2166.
15. Concha LAE, Michienzi K, Ma C, Hutchison AA (2007). Serum caffeine concentrations in preterm neonates. Am. J. Perinatol., 24: 39-47.
16. Daly JW, Butts-Lamb, P, Padgett W (1983). Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol., 3: 69-80
17. Davis PG, Doyle LW, Richards AL, Kelly EA, Ford GW, Davis NM, Callanan C (2000). Methylxanthines and sensorineural outcome at 14 years in children <1501 g birthweight. J. Paediatr. Child Health, 36: 47-50.
18. de Jong JW, de Jonge R, Keijzer E, Brandamente S (2000). The role of adenosine in preconditioning. Pharmacol. Ther., 87: 141-149.
19. Donovan JL, DeVane CL (2001). A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology. Psychopharmacol. Bull., 35: 30-48.
20. Ergenekon E, Dalgiç N, Aksoy E, Koç E, Atalay Y (2001). Caffeine intoxication in a premature neonate. Pediatr. Anaesth., 11: 737-739
21. Feldman RS, Meyer JS, Quenzer LF (1997). Principles of neuropsychopharmacology. Massachusetts, United States: Sinaver Associates Inc, pp. 615-623.
22. Finer NN, Higgins R, Kattwinkel J, Martin RJ (2006). Summary proceedings from the apnea of prematurity group. Pediatrics, 117: S47-S51.
23. Fredholm BB (1980). Are methylxanthine effects due to antagonism of endogenous adenosine? Trends. Pharmacol. Sci., 1: 129-132.
24. Galli E, Feijoo L (2002). Citocromo P-450 y su importancia clínica: revisión actualizada. Revista de Neuro-Psiquiatría, 65: 187-201.
25. Gong H, Simmons MS, Tashkin DP, HUI KK, Lee EY (1986). Bronchodilatador effects of caffeine in coffe. Chest, 89: 335-342.
26. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E (1996). Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J. Pediatr., 128: 470-478.
27. Harthorn MK (1974). The rate and depth of breathing in newborn infants during different sleep states. J. Physiol., 243: 101-113.
28. Henderson-Smart DJ, Steer P (2001). Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst. Rev., 3: CD000140.
29. Hoecker C, Nelle M, Poeschl J, Beedgen B, Linderkamp O (2002). Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics, 109: 784-787.
30. Jacobson KA, Zhan-Guo Gao (2006). Adenosine receptors as therapeutic targets. Nat. Rev., 5: 247-264.
31. Kuzemko JA, Paala J (1973). Apnoeic attacks in the newborn treated with aminophylline. Arch. Dis. Child, 48: 404-406.
32. Lagercrantz H (1995). Improved understanding of respiratory control-- implications for the treatment of apnoea. Eur. J. Pediatr., 154: S10-12
33. Lee HS, Khoo YM, Chirino-Barcelo Y, Tan KL, Ong D (2002). Caffeine in apnoeic Asian neonates: a sparse data analysis. Br. J. Clin. Pharmacol., 54: 31-37.
34. Lee TC, Charles BG, Steer PA, Flenady VJ (1996). Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment forapnea of prematurity. Ther. Drug Monit., 18: 288-293.
35. Lopes AJM (2001). Neonatal apnea. J. Pediatr., 77: S97-S103.
36. Martha M, Martin RJ (1992). Apnea of prematurity. Clin. Perinatol., 19: 789-808.
37. Martin RJ, Abu-Shaweesh JM (2005). Control of breathing and neonatal apnea. Biol. Neonate, 87: 288-295.
38. Martin RJ, Miller MJ, Carlo WA (1986). Pathogenesis of apnea in preterm infants. J. Pediatr., 109: 733-741.
39. Martin RJ, Okken A, Rubin D (1979). Arterial oxygen tension during active and quiet sleep in the normal neonate. J. Pediatr., 94: 271-274.
40. McCallum AD, Duke T (2007). Evidence behind the WHO guidelines: Hospital care for children: Is caffeine useful in the prevention of apnoea of prematurity? J. Trop. Pediatr., 53: 76-77.
41. McNamara DG, Nixon GM, Anderson BJ (2004). Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia. Pediatr. Anesth., 14: 541-550.
42. Menkes D (1984). Trauma y asfixia perinatal. In: Avery ME, Taeusch W. Manual del Recién Nacido. México: Interamericana McGraw-Hill, pp. 694-695.
43. Miller JM, Fanaroff AA, Martin JR (1997). Respiratory disorders in preterm and term infants. In: Fanaroff AA, Martin. Neonatal perinatal medicine. Diseases of the fetus and infant. United States: Mosby, pp. 1040-1065.
44. Miller MJ, Martin RJ (1992). Pathophysiology of apnea of prematurity. In: Polin RA, Fox WW. Fetal and neonatal physiology. Philadelphia, United States: WB Saunders, 1: 872-885.
45. Natarajan G, Lulic-Botica M, Aranda JV (2007). Pharmacology Review: Clinical Pharmacology of caffeine in the newborn. Neo Rev., 5: 214-221.
46. National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring (1987). Sept 29 to Oct 1. Pediatrics., 79: 292-299.
47. Neonatal formulary 5 (2007). Caffeine citrate (commentary) Neonatal use of caffeine: p3.[http://www.blackwellpublishing.com/medicine/bmj/nnf5/pdfs/commentary/caffeine.pdf].
48. Olmos-Hernández A, Trujillo-Ortega ME, Alonso-Spilsbury M, Ramírez-Necoechea R, Mota-Rojas D (2008). Foetal monitoring, uterine dynamics and reproductive performance in spontaneous farrowing sows. J. Appl. Anim. Res., 33: 181-185.
49. Orozco-Gregorio H, Mota-Rojas D, Alonso-Spilsbury M (2008). Shortterm neurophysiologic consequences of intrapartum asphyxia in piglets born by spontaneous parturition. Int. J. Neurosci., 118: 1299-1315.
50. Orozco-Gregorio H, Mota-Rojas D, Bonilla-Jaime H, Trujillo-Ortega ME, Becerril-Herrera M, Hernández-González R, Villanueva-García D (2010). Effects of administration of caffeine on metabolic variables in neonatal pigs with peripartum asphyxia. Am. J. Vet. Res., 71: 1214-1219.
51. Rigatto H (1992). Control of breathing in fetal life and onset and control of breathing in the neonate. In: Polin RA, Fox WW. Fetal and neonatal physiology. Philadelphia, United States: WB Saunders, 1: 790-800.
52. Rigatto H (1988). Control of breathing in the neonate and the sudden infant death syndrome. In: Fishman AP. Pulmonary Diseases and Disorders. New York, United States: McGraw-Hill, pp. 1363-1372.
53. Rigatto H (1986). Disorders of the control of breathing. In: Pediatrics Respiratory Diseases. Bethesda, United States: National Instruments of Health, pp. 20-25.
54. Roberts RJ (1984). Methylxanthine therapy: Caffeine and theophylline. In: Drug Therapy in Infants: Pharmacological Principles and Clinical Experience. Philadelphia, United States: WB Saunders, pp. 19-137.
55. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G (1995). Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J. Pediatr., 126: 605-610.
56. Scanlon JEM, Chin KC, Morgan MEI, Durbin GM, Hale KA, Brown SS (1992). Caffeine or theopylline for neonatal apnoea? Arch. Dis. Child, 67: 425-428.
57. Schmidt B (2005). Methylxanthine therapy for apnea of prematurity: Evaluation of treatment benefits and risks at age 5 years in the international caffeine for apnea of prematurity (CAP) trial. Biol. Neonate, 88: 208-213.
58. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W (2006). Caffeine therapy for apnea of prematurity. N. Eng. J. Med., 354: 2112-2121.
59. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W (2007). Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med., 357: 1893-1902.
60. Sung LH, Moi KM, Chirino BY, Leong TK, Ong D (2002). Caffeine in apnoeic Asia neonates: A sparse data analysis. J. Clin. Pharmacol., 54: 31-37.
61. Undem BJ, Lichtenstein LM (2005). Drug used in the treatment of Asthma. In: Brunton L, Lazo J, Parker K. Goodman and Gillman's The Pharmacological Basis of Therapeutics. McGraw Hill Publishing, p. 733.
62. Vohr RB (2000). Survival of the extremely preterm infant in North America in the 1990s. Clin. Perinatol., 27: 255-262.
63. Walther FJ, Erickson R, Sims ME (1990). Cardiovascular effects of caffeine therapy in preterm infants. Am. J. Dis. Child, 144: 1164-1166.
64. Zanardo V, Dani C, Trevisanuto D, Meneghetti S, Guglielmi A, Zacchello G, Cantarutti F (1995). Methylxanthines increase renal calcium excretion in preterm infants. Biol. Neonate, 68: 169-174.